Kepivance

Active Ingredient(s): Palifermin
FDA Approved: * December 15, 2004
Pharm Company: * AMGEN
Category: Cancer

Palifermin (trade name Kepivance, marketed by Biovitrum) is a truncated human recombinant keratinocyte growth factor (KGF)[1] produced in Escherichia coli. KGF stimulates the growth of cells that line the surface of the mouth and intestinal tract.[2] Contents 1 Therapeutic use(s) 2 Drug target and mechanism of action 3 Side effects 4 Administration 5 Drug interactions 6 Pre-clinical trials 6.1 Toxicology studies 7 Clinical trials 7.1 Phase I 7.2 Phase II ... [wikipedia]

* May have multiple approval dates, manufacturers, or labelers.

Dosage List

Kepivance 6.25 mg/1.2ml Intravenous Injection, Powder, Lyophilized, for Solution

NDC: 66658-112

Labeler:

Swedish Orphan Biovitrum Ab (Publ)

Kepivance 5.16 mg/1.2ml Intravenous Injection, Powder, Lyophilized, for Solution

NDC: 66658-113

Labeler:

Swedish Orphan Biovitrum Ab (Publ)